Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Technology Hardware & Equipment
EPIC: AMP
Latest Price: 4.13p  (0,00%)
52-week High: 7.13p
52-week Low: 2.25p
Market Cap: 5.58M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Amphion Innovations
www.amphionplc.com

Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.

Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

Full Amphion Innovations profile here
Is AMP a Buy, Sell or Hold?Get your FREE analysis of AMP
Pdf

Amphion Innovations appoints Katharine Cushing as strategic investment advisor based in NY

2nd Dec 2009, 9:43 am Amphion Innovations appoints Katharine Cushing as strategic investment advisor based in NY

Amphion Innovations PLC (AIM: AMP) said it has appointed Katharine Cushing as strategic investment advisor to assist Amphion and its partner companies in fund raising activities. She will be based in New York.

Cushing has extensive experience in working with high net worth individuals and families and assisting them in identifying investment opportunities.  She serves on the board of directors of the Arab Bankers Association of North America (ABANA) as well as the board of Providence Facilities Management, an affiliate of the Providence Performing Arts Center and is a member of the International Advisory Board for the Anthony Quinn Foundation.

Most recently she has been managing director at Detwiler Fenton Group Inc, a wholly owned subsidiary of Detwiler Fenton & Co, a Boston based financial services company.

Cushing began her career in 1983, at one of the oldest, privately-owned investment firms in the US, H.C. Wainwright & Co. where she was a fourth generation member of the Clark family, the majority owners and controlling partners for over 100 years.

Amphion builds shareholder value in high growth companies in the medical and technology sectors by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.

It does not invest in speculative technologies requiring long development timeframes or excessive capital investment; it looks for defensible core intellectual property and know-how for long-term competitive advantage, and growth potential in very large markets of at least US$1 billion in size. Each partner company is chosen with the goal of achieving an exit valuation in excess of US$100 million.

Amphion’s investments include 38.5 percent in Motif Biosciences, a 19.99 percent stake in Kromek, 20 percent in Myconostica Ltd, 15.3 percent in Firestar Software, 8.5 percent in Axcess International, 38.5 percent in Motif Biosciences, 50 percent in MSA Holdings B.S.C., 24.4 percent in M2M Imaging Corp, 25 percent in Private Markets, 14.6 percent in WellGen and 100 percent in DataTern.

Only last week, the company announced it has signed a partnership agreement with Kuwait University aimed at establishing and operating a technology transfer unit (TTU) at KU. This facility will be the first in-house TTU in Kuwait. Amphion has an established presence in the region, both through its partner company Motif BioSciences and its investor base, which includes members of prominent Gulf families.

Amphion has already been active for many years in commercialising IP in a number of universities in Europe and the US.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.